FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1) – Merck
- FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1) Merck
- FDA approves new drug that may help stop and even reverse a rare, fatal condition that doctors call a ‘ticking time bomb’ CNN
- FDA approves Merck’s drug for rare, deadly lung condition CNBC
- FDA Approves Potential ‘Game Changer’ for Pulmonary Arterial Hypertension BioSpace
- Merck’s $11.5 Billion Bet on Its Next Big Drug Finally Arrives The Wall Street Journal